| Company Name: | Curis, Inc. | | Ticker Symbol: | CRIS | | | WWW Address: | www.curis.com |
| CEO: | Daniel R. Passeri | | No. of Employees: | 33 |
| Common Issue Type: | CS | | Business Description: | Curis, Inc., is a drug discovery and development company that is committed to leveraging its innovative signaling pathway drug technologies in seeking to develop next generation targeted cancer therapies.
|
| | | Industry Information: | DRUGS - Biotechnology [more like this] |
|
| Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 4.12 |  0.1199 | 2.81 | 4.41 | 4.05 | 4.17 | 3.98 | - |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 331.8 | 80.5 | 1.43 | -0.21 | 0.00 | 0.0 | 0.0 | 5.51 - 2.66 |
|
| KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 4.12 | $ | | PE Ratio - LTM | 0.0 | |
| Market Capitalisation | 331.8 | mil |
| Latest Shares Outstanding | 80.5 | mil |
| Earnings pS (EPS) | -0.21 | $ |
| Dividend pS (DPS) | 0.00 | ¢ |
| Dividend Yield | 0.0 | % |
| Dividend Payout Ratio | | % |
| Revenue per Employee | 514,303 | $ |
| Effective Tax Rate | 0.0 | % |
| Float | 61.5 | mil |
| Float as % of Shares Outstanding | 76.8 | % |
| Foreign Sales | | mil |
| Domestic Sales | | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 136.10 | % |
| Research & Devlopment (R&D) as % of Revenue | 172.00 | % |
| Gross Profit Margin | 98.7 | % |
| EBITDA Margin | 0.0 | % |
| Pre-Tax Profit Margin | 0.0 | % |
| Assets Turnover | 0.1 | % |
| Return on Assets (ROA) | -32.8 | % |
| Return on Equity (ROE) | 0.0 | % |
| Return on Capital Invested (ROCI) | -35.6 | % |
| Current Ratio | 14.2 | |
| Leverage Ratio (Assets/Equity) | 2.2 | |
| Interest Cover | 0.0 | |
| Total Debt/Equity (Gearing Ratio) | 1.00 | |
| LT Debt/Total Capital | 50.0 | % |
| Working Capital pS | 0.60 | $ |
| Cash pS | 0.12 | $ |
| Book-Value pS | 0.38 | $ |
| Tangible Book-Value pS | 0.26 | $ |
| Cash Flow pS | -0.26 | $ |
| Free Cash Flow pS | -0.30 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 10.97 | |
| Price/Tangible Book Ratio | 15.60 | |
| Price/Cash Flow | -15.6 | |
| Price/Free Cash Flow | -13.8 | |
| P/E as % of Industry Group | 0.0 | % |
| P/E as % of Sector Segment | 0.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Type of Payment | - |
| Dividend Rate | 0.00 |
| Current Dividend Yield | 0.0 |
| 5-Y Average Dividend Yield | 0.0 |
| Payout Ratio | 0.0 |
| 5-Y Average Payout Ratio | 0.0 |
| |
| |
| |
| |
| |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | |
| |
| PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | -0.2 | 98 | 8,844 | 45,260 |
| 4 Weeks | 4.50 | 3.06 | 3.22 | 28.0 | 119 | 9,222 | 184,433 |
| 13 Weeks | 4.50 | 2.66 | 2.80 | 47.1 | 134 | 5,664 | 356,833 |
| 26 Weeks | 4.50 | 2.66 | 3.16 | 30.4 | 106 | 4,389 | 544,253 |
| 52 Weeks | 5.51 | 2.66 | 4.47 | -7.8 | 72 | 4,372 | 1,088,657 |
| YTD | 4.50 | 2.66 | - | 20.1 | 103 | 4,770 | 453,193 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 4.27 | 4.04 | 3.49 | 3.37 | 3.61 | 1.43 | 2.10 |
|
| |
| GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | 5.54 | 9.1 | -5.06 |
| Income | 0.00 | 0.0 | 0.00 |
| Dividend | 0.00 | 0.0 | 0.00 |
| Capital Spending | 30.37 | NA | 64.71 |
| R&D | 1.76 | NA | 12.56 |
| Normalized Inc. | 0.00 | NA | 0.00 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | -91.6 | -91.6 | 15.0 |
| Earnings % | 0.0 | 0.0 | 0.0 |
| EPS % | -100.0 | -100.0 | 0.0 |
| EPS $ | -0.09 | -0.09 | -0.08 |
|
| |
| SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 75.78 |
| Current Ratio | 14.3 |
| Quick Ratio (Acid Test) | 14.2 |
| Liquidity Ratio (Cash) | 13.96 |
| Receivables Turnover | 35.7 |
| Average Collection Period | 10 |
| Working Capital/Equity | 154.3 |
| Working Capital pS | 0.66 |
| Cash-Flow pS | -0.20 |
| Free Cash-Flow pS | -0.19 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | 5.62 |
| Financial Leverage Ratio (Assets/Equity) | 2.0 |
| Debt Ratio | 50.9 |
| Total Debt/Equity (Gearing Ratio) | 0.87 |
| LT Debt/Equity | 0.87 |
| LT Debt/Capital Invested | 49.2 |
| LT Debt/Total Liabilities | 84.1 |
| Interest Cover | 0.0 |
| Interest/Capital Invested | 0.31 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 17.47 |
| Tobin's Q Ratio | 4.76 |
| Current P/E Ratio - LTM | 0.00 |
| Enterprise Value (EV)/EBITDA | -34.69 |
| Enterprise Value (EV)/Free Cash Flow | -19.17 |
| Dividend Yield | 0.0 |
| Price/Tangible Book Ratio - LTM | 15.60 |
| Price/Book Ratio - LTM | 10.97 |
| Price/Cash Flow Ratio | -15.6 |
| Price/Free Cash Flow Ratio - LTM | -13.8 |
| Price/Sales Ratio | 44.32 |
| P/E Ratio (1 month ago) - LTM | 0.0 |
| P/E Ratio (26 weeks ago) - LTM | 105.3 |
| P/E Ratio (52 weeks ago) - LTM | 0.0 |
| 5-Y High P/E Ratio | 0.0 |
| 5-Y Low P/E Ratio | 0.0 |
| 5-Y Average P/E Ratio | 0.0 |
| Current P/E Ratio as % of 5-Y Average P/E | |
| P/E as % of Industry Group | 0.0 |
| P/E as % of Sector Segment | 0.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 0.0 |
| PER SHARE FIGURES |
| LT Debt pS | 0.37 |
| Current Liabilities pS | 0.05 |
| Tangible Book Value pS - LTM | 0.26 |
| Book Value pS - LTM | 0.38 |
| Capital Invested pS | 0.80 |
| Cash pS - LTM | 0.12 |
| Cash Flow pS - LTM | -0.26 |
| Free Cash Flow pS - LTM | -0.30 |
| Earnings pS (EPS) | -0.21 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | -90.14 |
| Free Cash Flow Margin 5YEAR AVG | -74.54 |
| Net Profit Margin | -96.7 |
| Net Profit Margin - 5YEAR AVRG. | -44.1 |
| Equity Productivity | 0.50 |
| Return on Equity (ROE) | 0.0 |
| Return on Equity (ROE) - 5YEAR AVRG. | 0.0 |
| Capital Invested Productivity | 0.26 |
| Return on Capital Invested (ROCI) | -25.6 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | -13.0 |
| Assets Productivity | 0.30 |
| Return on Assets (ROA) | -23.5 |
| Return on Assets (ROA) - 5YEAR AVRG. | -11.7 |
| Gross Profit Margin | 98.7 |
| Gross Profit Margin - 5YEAR AVRG. | 0.0 |
| EBITDA Margin - LTM | 0.0 |
| EBIT Margin - LTM | 0.0 |
| Pre-Tax Profit Margin | -96.7 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | -83.8 |
| Effective Tax Rate | 0.0 |
| Effective Tax Rate - 5YEAR AVRG. | 0.0 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 19 |
| Revenue per Employee | 514,303 |
| Net Income per Employee | -497,482 |
| Average Collection Period | 19 |
| Receivables Turnover | 35.7 |
| Day's Inventory Turnover Ratio | |
| Inventory Turnover | 0.0 |
| Inventory/Sales | 0.0 |
| Accounts Payble/Sales | 14.76 |
| Assets/Revenue | 3.33 |
| Net Working Capital Turnover | 0.32 |
| Fixed Assets Turnover | 1.31 |
| Total Assets Turnover | 0.3 |
| Revenue per $ Cash | 1.33 |
| Revenue per $ Plant | 39.09 |
| Revenue per $ Common Equity | 0.50 |
| Revenue per $ Capital Invested | 0.26 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 61.4 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 71.0 |
| Research & Devlopment (R&D) as % of Revenue | 91.3 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 91.3 |
|
|  
|
| |
 |  |
